(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Less than a month after the company from which it split more than three years ago, bluebird bio, sold for less than $30 million, the Cambridge drugmaker is being acquired by its partner Bristol Myers ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

(NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M net of estimated cash).

2seventy bio, the cell therapy spinout of Bluebird bio, is selling itself to Bristol Myers Squibb after losing most of its ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...